Concord Biotech Ltd Technical Momentum Shifts Amid Prolonged Downtrend

Current Price Action and Market Context

As of 27 Apr 2026, Concord Biotech’s share price closed at ₹1,015.85, down 3.35% from the previous close of ₹1,051.10. The stock traded within a range of ₹1,013.00 to ₹1,067.55 during the day, hovering near its 52-week low of ₹1,013.00 and significantly below its 52-week high of ₹2,149.90. This wide gap between the high and low underscores the stock’s volatile nature over the past year.

Comparatively, the broader market benchmark, the Sensex, has outperformed Concord Biotech substantially. The stock’s year-to-date return stands at -24.5%, while the Sensex has gained 10.04% over the same period. Over the last year, Concord Biotech’s decline of 38.65% starkly contrasts with the Sensex’s modest 3.93% loss, highlighting sector-specific or company-specific challenges.

Technical Indicator Analysis: Momentum and Trend Shifts

The technical landscape for Concord Biotech reveals a nuanced picture. The overall technical trend has shifted from bearish to mildly bearish, signalling a tentative easing of downward momentum but no definitive reversal yet. The Moving Average Convergence Divergence (MACD) indicator remains bearish on the weekly timeframe, suggesting that the stock’s momentum is still skewed towards the downside. The monthly MACD reading is inconclusive, indicating a lack of strong directional momentum over the longer term.

The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This suggests that the stock is neither overbought nor oversold, leaving room for potential directional moves but no immediate extremes.

Bollinger Bands provide further insight into volatility and trend strength. On the weekly chart, the bands are bearish, reflecting price pressure near the lower band and increased volatility. The monthly Bollinger Bands are mildly bearish, indicating a softer but still negative trend over the longer horizon.

Daily moving averages reinforce the bearish outlook, with the stock trading below key averages, signalling continued selling pressure. The Know Sure Thing (KST) oscillator is bearish on the weekly timeframe, aligning with the MACD’s negative momentum. However, the Dow Theory readings offer a mixed view: mildly bullish on the weekly scale but mildly bearish monthly, suggesting short-term attempts at recovery amid longer-term caution.

On-Balance Volume (OBV) analysis adds an interesting dimension. While the weekly OBV shows no clear trend, the monthly OBV is bullish, implying that despite price weakness, accumulation may be occurring at a slower pace over the longer term. This divergence between volume and price could hint at underlying investor interest that has yet to translate into price gains.

Mojo Score and Ratings Update

Concord Biotech’s MarketsMOJO score currently stands at 34.0, categorised as a ‘Sell’ rating. This represents an upgrade from the previous ‘Strong Sell’ grade assigned on 24 Apr 2026, signalling a slight improvement in the stock’s outlook. The small-cap classification reflects the company’s market capitalisation and associated liquidity considerations.

The upgrade in rating is consistent with the technical trend’s shift from strongly bearish to mildly bearish, though the overall sentiment remains cautious. Investors should note that the Mojo Grade is a composite measure incorporating fundamentals, technicals, and momentum, and the current ‘Sell’ rating suggests limited near-term upside potential.

Comparative Performance and Sector Context

Within the Pharmaceuticals & Biotechnology sector, Concord Biotech’s performance has lagged behind broader indices and peers. The sector itself has experienced mixed trends, with some companies benefiting from innovation and regulatory approvals, while others face pricing pressures and competitive challenges.

Concord’s underperformance relative to the Sensex and sector benchmarks over multiple timeframes—1 week (-6.05% vs. -2.33%), 1 month (-2.11% vs. +3.50%), and year-to-date (-24.5% vs. +10.04%)—raises concerns about its ability to regain investor confidence in the near term.

Technical Outlook and Investor Considerations

From a technical perspective, the stock’s proximity to its 52-week low and persistent bearish signals on key indicators such as MACD and moving averages suggest that downside risks remain elevated. However, the mildly bullish Dow Theory weekly reading and bullish monthly OBV hint at potential pockets of strength that could be monitored for early signs of recovery.

Investors should watch for a sustained break above daily moving averages and a positive crossover in MACD to confirm any meaningful trend reversal. Additionally, an RSI move above 50 on weekly or monthly charts could signal improving momentum. Until such confirmations, caution is warranted given the prevailing technical and fundamental headwinds.

Summary

Concord Biotech Ltd’s technical parameters indicate a tentative easing of bearish momentum, yet the stock remains under pressure with a ‘Sell’ rating and a Mojo Score of 34.0. Key technical indicators such as MACD, moving averages, and Bollinger Bands continue to signal caution, while volume-based metrics suggest some underlying accumulation. The stock’s significant underperformance relative to the Sensex and sector peers highlights the challenges ahead.

For investors, the current environment calls for vigilance and a focus on technical confirmation before considering fresh exposure. Monitoring momentum indicators and price action near critical support and resistance levels will be crucial in assessing any potential turnaround.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today